Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: Insights from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPRIT) Trial

Journal of the American College of Cardiology

Volumn 47, Issue 4, 2006, Pages 715-718

  Puma, Joseph A ^a   Banko, Lesan T ^a   Pieper, Karen S ^b   Sacchi, Terrence J ^a   O'Shea, J Conor ^b   Dery, Jean Pierre ^b   Tcheng, James E ^b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; ST SEGMENT ELEVATION; STROKE; SURVIVAL RATE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STENTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 32644447353     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.08.075     Document Type: Article

References (11)

1. V. Fuster, L. Badimon, J. Badimon The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 326 1992 242 250
2. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty the EPIC Investigation N Engl J Med 330 1994 956 961
3. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
4. The CAPTURE Investigators Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study Lancet 349 1997 1429 1435
5. The IMPACT-II Investigators Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II Lancet 349 1997 1422 1428
6. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty randomized efficacy study of tirofiban for outcomes and restenosis Circulation 96 1997 1445 1453
7. The EPISTENT Investigators Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Lancet 352 1998 87 92
8. D.F. Kong, R.M. Califf, D.P. Miller Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease Circulation 98 1998 2829 2835
9. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomized, placebo-controlled trial Lancet 356 2000 2037 2044
10. J.C. O'Shea, G. Hafley, S. Greenberg Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial JAMA 285 2001 2468 2473
11. J.C. O'Shea, C. Buller, W. Cantor Long term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention JAMA 287 2002 618 621